Pyxis Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Pyxis Oncology, Inc. (PYXS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.71 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 675.96K shares, a 27.51% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 3.04M shares, a 2.23% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 414.81K shares, a 84.92% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 717.21K shares, a 1136.03% increase year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.17M shares, a 22.02% increase from fiscal 2024.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 4.24M shares, a 292.70% increase from fiscal 2023.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.08M shares, a 8.45% decline from fiscal 2022.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.18M shares, a 81.45% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 675.96K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 3.71M shares 10-Q · filed 2026-08-13 | 4.13M shares derived: sum of 3 quarters · filed 2026-08-13 | 4.84M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 3.04M shares 10-Q · filed 2026-05-14 | 3.45M shares derived: sum of 2 quarters · filed 2026-05-14 | 4.17M shares derived: sum of 3 quarters · filed 2026-05-14 | 5.10M shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 414.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 1.13M shares derived: sum of 2 quarters · filed 2026-03-23 | 2.06M shares derived: sum of 3 quarters · filed 2026-03-23 | 5.17M shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 717.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 1.65M shares derived: sum of 2 quarters · filed 2025-11-03 | 4.75M shares 10-Q · filed 2025-11-03 | 7.50M shares derived: sum of 4 quarters · filed 2025-11-03 |
| 2025-06-30 | 932.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 4.04M shares 10-Q · filed 2025-08-14 | 6.79M shares derived: sum of 3 quarters · filed 2025-08-14 | 6.85M shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 3.10M shares 10-Q · filed 2025-05-15 | 5.86M shares derived: sum of 2 quarters · filed 2025-05-15 | 5.91M shares derived: sum of 3 quarters · filed 2025-05-15 | 6.10M shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | 2.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 2.81M shares derived: sum of 2 quarters · filed 2025-03-18 | 2.99M shares derived: sum of 3 quarters · filed 2025-03-18 | 4.24M shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 58.02K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 240.62K shares derived: sum of 2 quarters · filed 2024-11-12 | 1.49M shares 10-Q · filed 2024-11-12 | 2.09M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 182.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 1.43M shares 10-Q · filed 2024-08-14 | 2.03M shares derived: sum of 3 quarters · filed 2024-08-14 | 2.43M shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 1.24M shares 10-Q · filed 2024-05-14 | 1.85M shares derived: sum of 2 quarters · filed 2024-05-14 | 2.25M shares derived: sum of 3 quarters · filed 2024-05-14 | 2.26M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 603.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 1.00M shares derived: sum of 2 quarters · filed 2024-03-21 | 1.01M shares derived: sum of 3 quarters · filed 2024-03-21 | 1.08M shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 396.82K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 407.21K shares derived: sum of 2 quarters · filed 2023-11-07 | 474.73K shares 10-Q · filed 2023-11-07 | 546.52K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 10.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 77.90K shares 10-Q · filed 2023-08-11 | 149.69K shares derived: sum of 3 quarters · filed 2023-08-11 | 728.90K shares derived: sum of 4 quarters · filed 2023-08-11 |
| 2023-03-31 | 67.51K shares 10-Q · filed 2023-05-11 | 139.31K shares derived: sum of 2 quarters · filed 2023-05-11 | 718.52K shares derived: sum of 3 quarters · filed 2023-05-11 | 892.53K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 71.79K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | 651.00K shares derived: sum of 2 quarters · filed 2023-03-22 | 825.02K shares derived: sum of 3 quarters · filed 2023-03-22 | 1.18M shares 10-K · filed 2023-03-22 |
| 2022-09-30 | 579.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 753.23K shares derived: sum of 2 quarters · filed 2022-11-01 | 1.11M shares 10-Q · filed 2022-11-01 | 3.79M shares derived: sum of 4 quarters · filed 2022-11-01 |
| 2022-06-30 | 174.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 527.28K shares 10-Q · filed 2022-08-15 | 3.21M shares derived: sum of 3 quarters · filed 2022-08-15 | |
| 2022-03-31 | 353.26K shares 10-Q · filed 2022-05-13 | 3.03M shares derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2021-12-31 | 2.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 6.35M shares 10-K · filed 2022-03-29 | ||
| 2021-09-30 | 3.67M shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |